Glaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024. In the quarter to June 2026, revenue grew 49.5%, EPS grew 8.82%, free cash flow grew 211.8% and total debt fell 2.15%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow GKOS
Glaukos Corporation (GKOS) EV/Sales
As of 16 October 2026, Glaukos Corporation (GKOS) trades at a EV/Sales of 15.9×. Over the past ten years it has ranged from −0.3× (September 2015) to 23.7× (December 2024); the current reading is higher than 89% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 12.9× | (37.89%) |
| FY2024 | 20.7× | 60.08% |
| FY2023 | 12.9× | 54.89% |
| FY2022 | 8.4× | 7.63% |
| FY2021 | 7.8× | (45.38%) |
| FY2020 | 14.2× | 75.23% |
| FY2019 | 8.1× | (20.44%) |
| FY2018 | 10.2× | 98.90% |
| FY2017 | 5.1× | (42.45%) |
| FY2016 | 8.9× | 82.39% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.5× | 17.94% |
| Mar 2026 | 11.5× | (10.91%) |
| Dec 2025 | 12.9× | 27.07% |
| Sep 2025 | 10.1× | (26.75%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 1.5× |
| BRKR Bruker Corporation compare | 2.9× |
| PODD Insulet Corporation compare | 3.3× |
| GMED Globus Medical, Inc. compare | 3.4× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.6× |
| HAE Haemonetics Corporation compare | 4.7× |
| PEN Penumbra, Inc. compare | 8.0× |
| GKOS Glaukos Corporation | 15.9× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)